Thus, the overall findings of our study conclude that CHSY1-mediated CS may promote CD44 activity and consequently regulate integrin expression in glioma cells, thereby serving as a potential pathway for therapeutic targeting in glioma. The gene discussed is CD44; the disease is central nervous system cancer.